Etzer Darout
Stock Analyst at Barclays
(4.48)
# 310
Out of 5,138 analysts
154
Total ratings
52.8%
Success rate
21.49%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Etzer Darout
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRVS Corvus Pharmaceuticals | Maintains: Overweight | $16 → $28 | $21.33 | +31.27% | 2 | Jan 21, 2026 | |
| CTMX CytomX Therapeutics | Maintains: Overweight | $6 → $8 | $5.15 | +55.34% | 13 | Jan 20, 2026 | |
| ANAB AnaptysBio | Maintains: Overweight | $55 → $78 | $44.80 | +74.11% | 4 | Jan 20, 2026 | |
| XNCR Xencor | Maintains: Overweight | $23 → $26 | $12.80 | +103.13% | 8 | Dec 17, 2025 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $45 → $52 | $45.47 | +14.36% | 8 | Dec 17, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $88 → $108 | $82.54 | +30.85% | 5 | Dec 17, 2025 | |
| JANX Janux Therapeutics | Maintains: Overweight | $48 → $29 | $13.31 | +117.88% | 3 | Dec 17, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Overweight | $9 → $10 | $2.49 | +301.61% | 2 | Dec 17, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Underweight | $21 → $24 | $25.69 | -6.56% | 3 | Dec 17, 2025 | |
| CCCC C4 Therapeutics | Maintains: Overweight | $10 → $5 | $2.07 | +141.55% | 6 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $18 | $12.38 | +45.40% | 7 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $18 | $16.47 | +9.29% | 3 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $56 | $36.66 | +52.76% | 11 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $119 | $69.08 | +72.26% | 4 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $35 | $20.27 | +72.67% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $28 | $8.60 | +225.58% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $101 → $115 | $104.35 | +10.21% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $58 → $56 | $57.59 | -2.76% | 3 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $41 | $44.95 | -8.79% | 5 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $61 | $4.49 | +1,258.57% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $48 | $33.98 | +41.25% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $68.05 | +83.69% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $142 | $118.45 | +19.88% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $3 | $1.75 | +71.92% | 10 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $13 | $6.53 | +99.23% | 4 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 → $143 | $114.36 | +25.04% | 4 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $22 → $3 | $4.02 | -25.37% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $18.39 | +90.32% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $1.50 | +4,114.05% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $27 | $2.05 | +1,217.07% | 7 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $132 → $134 | $106.97 | +25.27% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 → $48 | $32.92 | +45.81% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $118 → $120 | $143.90 | -16.61% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $6 | $1.14 | +426.32% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $82 | $89.47 | -8.35% | 4 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $19 | $5.87 | +223.68% | 2 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $170 | $360.76 | -52.88% | 2 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $38 | $92.86 | -59.08% | 2 | Sep 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $52 | $4.23 | +1,129.31% | 1 | Mar 28, 2018 |
Corvus Pharmaceuticals
Jan 21, 2026
Maintains: Overweight
Price Target: $16 → $28
Current: $21.33
Upside: +31.27%
CytomX Therapeutics
Jan 20, 2026
Maintains: Overweight
Price Target: $6 → $8
Current: $5.15
Upside: +55.34%
AnaptysBio
Jan 20, 2026
Maintains: Overweight
Price Target: $55 → $78
Current: $44.80
Upside: +74.11%
Xencor
Dec 17, 2025
Maintains: Overweight
Price Target: $23 → $26
Current: $12.80
Upside: +103.13%
Scholar Rock Holding
Dec 17, 2025
Maintains: Overweight
Price Target: $45 → $52
Current: $45.47
Upside: +14.36%
Protagonist Therapeutics
Dec 17, 2025
Maintains: Overweight
Price Target: $88 → $108
Current: $82.54
Upside: +30.85%
Janux Therapeutics
Dec 17, 2025
Maintains: Overweight
Price Target: $48 → $29
Current: $13.31
Upside: +117.88%
Iovance Biotherapeutics
Dec 17, 2025
Maintains: Overweight
Price Target: $9 → $10
Current: $2.49
Upside: +301.61%
Celldex Therapeutics
Dec 17, 2025
Maintains: Underweight
Price Target: $21 → $24
Current: $25.69
Upside: -6.56%
C4 Therapeutics
Dec 17, 2025
Maintains: Overweight
Price Target: $10 → $5
Current: $2.07
Upside: +141.55%
Dec 17, 2025
Maintains: Overweight
Price Target: $16 → $18
Current: $12.38
Upside: +45.40%
Dec 17, 2025
Upgrades: Equal-Weight
Price Target: $16 → $18
Current: $16.47
Upside: +9.29%
Dec 9, 2025
Maintains: Overweight
Price Target: $36 → $56
Current: $36.66
Upside: +52.76%
Dec 9, 2025
Maintains: Overweight
Price Target: $70 → $119
Current: $69.08
Upside: +72.26%
Nov 24, 2025
Maintains: Overweight
Price Target: $22 → $35
Current: $20.27
Upside: +72.67%
Nov 24, 2025
Maintains: Overweight
Price Target: $11 → $28
Current: $8.60
Upside: +225.58%
Nov 24, 2025
Maintains: Overweight
Price Target: $101 → $115
Current: $104.35
Upside: +10.21%
Nov 7, 2025
Maintains: Overweight
Price Target: $58 → $56
Current: $57.59
Upside: -2.76%
Nov 5, 2025
Maintains: Equal-Weight
Price Target: $40 → $41
Current: $44.95
Upside: -8.79%
Oct 13, 2025
Initiates: Overweight
Price Target: $61
Current: $4.49
Upside: +1,258.57%
Oct 13, 2025
Initiates: Overweight
Price Target: $48
Current: $33.98
Upside: +41.25%
Oct 13, 2025
Initiates: Overweight
Price Target: $125
Current: $68.05
Upside: +83.69%
Oct 13, 2025
Initiates: Overweight
Price Target: $142
Current: $118.45
Upside: +19.88%
Sep 17, 2025
Assumes: Overweight
Price Target: $3
Current: $1.75
Upside: +71.92%
Sep 2, 2025
Maintains: Buy
Price Target: $9 → $13
Current: $6.53
Upside: +99.23%
Mar 11, 2025
Maintains: Outperform
Price Target: $130 → $143
Current: $114.36
Upside: +25.04%
Feb 11, 2025
Downgrades: Market Perform
Price Target: $22 → $3
Current: $4.02
Upside: -25.37%
Dec 6, 2024
Initiates: Outperform
Price Target: $35
Current: $18.39
Upside: +90.32%
Dec 6, 2024
Initiates: Outperform
Price Target: $63
Current: $1.50
Upside: +4,114.05%
Nov 14, 2024
Maintains: Outperform
Price Target: $28 → $27
Current: $2.05
Upside: +1,217.07%
Nov 13, 2024
Maintains: Outperform
Price Target: $132 → $134
Current: $106.97
Upside: +25.27%
Nov 8, 2024
Reiterates: Outperform
Price Target: $46 → $48
Current: $32.92
Upside: +45.81%
Oct 30, 2024
Maintains: Market Perform
Price Target: $118 → $120
Current: $143.90
Upside: -16.61%
May 10, 2024
Maintains: Market Perform
Price Target: $7 → $6
Current: $1.14
Upside: +426.32%
Apr 26, 2024
Maintains: Outperform
Price Target: $80 → $82
Current: $89.47
Upside: -8.35%
Apr 25, 2023
Maintains: Outperform
Price Target: $20 → $19
Current: $5.87
Upside: +223.68%
Feb 3, 2022
Upgrades: Buy
Price Target: $170
Current: $360.76
Upside: -52.88%
Sep 9, 2020
Maintains: Buy
Price Target: $27 → $38
Current: $92.86
Upside: -59.08%
Mar 28, 2018
Maintains: Outperform
Price Target: $54 → $52
Current: $4.23
Upside: +1,129.31%